Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis

Abstract

Objective To evaluate and compare the efficacy and safety of entecavir and tenofovir in treatment of chronic hepatitis B. Methods The researches on entecavir and tenofovir in treatment of chronic hepatitis B were searched in PubMed/Medicine, EMBase, Cochrane Library databases until November 2017.Two authors independently extracted and summarized the data.Stata 12.0 software was used to analyze the data. Results A total of 13 studies were included in this Meta-analysis.In the aspect of therapeutic effectiveness of tenofovir and entecavir for HBV-DNA, the research objects were divided into two subgroups according to the use time of oral antiviral drug, and the relative risk(RR)and confidence interval(CI)of 24 weeks and 48 weeks subgroup were as follows: RR=1.00, 95% CI(0.90-1.11), I2=30%, P=0.152; RR=1.08, 95% CI(1.00-1.16), I2=53%, P=0.016. Conclusion Tenofovir has a similar efficacy in HBV-DNA negative conversion ratio compared with entecavir in follow-up time 24 and 48 weeks. Key words: Tenofovir; Entecavir; Chronic hepatitis B; Meta-analysis